Last reviewed 2026-05-14 · How we verify

[14C]-GSK1278863 oral solution

GlaxoSmithKline · Phase 1 active Small molecule

[14C]-GSK1278863 oral solution is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	[14C]-GSK1278863 oral solution
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-GSK1278863 oral solution CI brief — competitive landscape report
[14C]-GSK1278863 oral solution updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about [14C]-GSK1278863 oral solution

What is [14C]-GSK1278863 oral solution?

[14C]-GSK1278863 oral solution is a Small molecule drug developed by GlaxoSmithKline.

Who makes [14C]-GSK1278863 oral solution?

[14C]-GSK1278863 oral solution is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is [14C]-GSK1278863 oral solution in?

[14C]-GSK1278863 oral solution is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline